BioSpace News Archive

Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $251.9 million, or $2.95 per diluted share, during the second quarter of 2020, as compared to $238.3 million,

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced it will release its Q2 2020 financial results after the close on Wednesday, August 12, 2020.

This morning, Dr. Paul Bradley, co-founder and Chief Medical Officer of Scripta Insights, partner at BCG Medical Group, and Principal Investigator at Meridian Clinical Research’s internal medicine site in Savannah, Ga., dosed the very first patient in the nation’s first Phase 3 COVID-19 vaccine clinical trial

The advanced therapy medicinal products market may observe growth across the forecast period of 2019-2029 on the back of the advancements in the biotechnology sector on a large scale.

Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in phase 1 clinical development for non-small cell lung cancer and triple negative breast cancer.

Anesthesia is used to introduce an ample depth of unconsciousness during a medical procedure or surgery.

This report analyzes the current scenario and future prospects of the global diabetic foot ulcers treatment market. Rise in geriatric population and increase in people suffering from chronic diseases such as diabetes and HIV are expected to increase at a rapid pace in the next few years.

- Plans to Initiate Phase 1 Clinical Trial This Year - Expands Corporate Advisors with Board of Directors and Scientific Advisory Board Appointments

Agendia, Inc., a world leader in precision oncology for breast cancer, announced the publication of MINDACT trial data in the July 27 issue of Communications Biology, a Nature Publishers Journal.

Aiming to provide better health management services to lung cancer patients, “Cloud Enabled Lung Cancer Care by Great Doctors” was officially launched in Shanghai on July 25, 2020.